rivaroxaban news from FierceBiotech
NewsCHMP recommends Bayer's Xarelto
Among a number of CHMP announced today was the committee's recommendation of Bayer's Xarelto, known generically as rivaroxaban. Xarelto, a blood-thinning pill to prevent clots in patients bedridden... Read more...
Bayer, J&J tout rivaroxaban data
In a head-to-head study against Sanofi's Lovenox, Bayer and J&J's oral anti-clotting drug rivaroxaban proved superior in preventing venous blood clots in patients who underwent total knee... Read more...
| Press ReleasesBayer Corporation, Johnson and Johnson Pharmaceutical Research and Development Clot-Drug Success Lifts U.S. ProspectsBayer Corporation, Johnson and Johnson Pharmaceutical Research and Development Clot-Drug Success Lifts U.S. Prospects NICE, France--Results from a pivotal Phase III clinical trial presented today Read more >> |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
